X Corp Sues Major Music Publishers in Antitrust Battle
Elon Musk's X Corp sues Sony, Universal & Warner for antitrust collusion over music licensing. Lawsuit alleges inflated rates & mass copyright takedowns. Full details inside.
Category : Search result: India pharmaceutical licensing
X Corp Sues Music Publishers Over Alleged Antitrust Conspiracy
Elon Musk's X Corp files a major antitrust lawsuit against 18 music publishers, alleging a conspiracy to inflate licensing fees. The platform claims it was forced to remove thousands of posts and suspend users.
EU's New DNA Rules: No Heavy-Handed Regulation for Big Tech
Google, Meta, Amazon, Microsoft, and Netflix will face voluntary rules under EU's Digital Networks Act, not binding regulations. The new framework aims to boost telecom investment. Read the details.
Why Indian Drug Makers Challenge Global Patents
Explore the high-stakes legal battles between Indian generic manufacturers and global pharma giants. Understand the impact on drug prices, accessibility, and the evolving IP landscape in India.
India Plans New Pharma Licence for Bulk Drugs to Boost Safety
India plans a major pharma licensing overhaul with a separate wholesale licence for bulk drugs and APIs to improve traceability and safety. This move follows global scrutiny over contaminated cough syrups and aims to regulate a $50-billion market.
Indian Pharma's Innovation Success in 2025
Indian pharmaceutical companies, long known for generics, saw their risky innovation bets yield major commercial success in 2025 through global deals and approvals. Discover the key players and what's next for 2026.
India's New Pharma Licence Regime to Fix Accountability
India plans a new wholesale licensing system for bulk drugs and a supplier database to enhance traceability and accountability in its $50-billion pharmaceutical market, following global safety concerns.
Generic Semaglutide to Create Rs 50,000 Cr Market
The patent expiry of semaglutide drugs will create a massive Rs 50 billion+ revenue opportunity for generic makers in India and globally over the next 12-15 months, boosting diabetes treatment access. Read the full analysis.
Generic Semaglutide to Create Rs 50bn+ Revenue Opportunity
Patent expiry of semaglutide drugs will create a Rs 50+ billion revenue chance for generic pharma firms in 12-15 months. Prices may drop up to 75%, boosting patient access. Read the full analysis.
Bihar Deputy CM Suspends Mines Inspector in Darbhanga
Bihar's Mines Minister Vijay Kumar Sinha suspends Darbhanga district mines inspector for serious irregularities. State to launch mass awareness camps on legal sand mining from Jan 16. Report illegal activities on helpline.
Indian Pharma Firms Eye Licensing Deals for Obesity Drugs
As patents expire, Indian drugmakers like Lupin and Ajanta Pharma are forging licensing and distribution deals for GLP-1 obesity drugs. The market is set for explosive growth. Explore the key partnerships and market dynamics.
Aurobindo Pharma buys Khandelwal Labs unit for ₹325 cr
Aurobindo Pharma strengthens its domestic formulations market with a ₹325 crore acquisition of Khandelwal Laboratories' non-oncology business. The deal includes 23 established brands and boosts presence in pain & anti-infective segments. Read more.
Drug Inspection Data Kept Secret, Public Safety at Risk?
India's drug regulator CDSCO refuses to disclose risk-based inspection details under RTI, sparking debate on transparency vs. commercial interests. Experts warn this secrecy endangers public health.
Nvidia's $20B Groq Deal: AI Chip War Escalates
Nvidia's massive $20 billion licensing agreement with Groq secures key AI inference technology and talent. Discover the deal's specifics, founder's windfall, and what's next.
Nvidia's $20B Groq Deal: Key Details on Payouts & Strategy
Nvidia's non-exclusive licensing deal with AI chip startup Groq, valued at ~$20B, triggers major payouts for shareholders & employees. Founder, CEO, and 90% of staff join Nvidia, while Groq continues independently. Explore the details.
Fermenta Biotech Ranked Among India's Best Workplaces
Fermenta Biotech Ltd. has been recognized as one of India's Best Workplaces in Pharmaceuticals, Healthcare & Biotech 2024 by Great Place To Work. Discover what makes their culture stand out.
India's 2026 Health Agenda: Drug Quality, TB, Innovation
India sets a 2026 health roadmap focusing on stringent drug quality, TB elimination, obesity, and a ₹4,200 crore innovation push. Will execution match ambition?
Pune residents fight noise, traffic from unchecked pubs
Pune's residential areas like Kalyaninagar & Baner face chaos from pubs in housing zones. Residents cite noise, safety issues & crippled infrastructure. Read about their fight for peace.
India's Music Revenue Jumps 40.5%, Yet Faces Payment Crisis
India's music creator revenues hit €80.5M in 2024, per CISAC. Yet, heavy reliance on streaming & under-licensed sectors threaten long-term growth. Industry demands fair royalties.
Everfast Strengthens India's Medicine Cold Chain Capabilities
Everfast Freight Forwarders launches a major cold chain expansion in India, enhancing storage for medicines and vaccines. Discover how this investment supports healthcare logistics.
Netflix Removing 100+ Originals in 2026
Netflix will pull more than 100 of its Original series and films in 2026 as licensing deals expire. Find out which popular shows like The Last Kingdom and She-Ra are leaving.
JioHotstar Series Questions India's Pharmaceutical System
JioHotstar's new series 'Pharma' ignites public debate on drug pricing, ethics, and accessibility in India's healthcare system. Read the full analysis.
India's AI Copyright Licensing Plan Sparks Debate
India's proposed mandatory AI licensing aims to protect creators' rights but risks stifling innovation. Experts weigh the complex trade-offs in this new policy.
India Pharma Targets $500B, Innovation Hub by 2047
India's pharmaceutical industry gears up for a critical 5-year phase from 2026, aiming to become a $500 billion innovation hub by 2047. Learn how it plans to tackle challenges and seize opportunities.
Afghanistan Picks India Over Pakistan for Pharma Supplies
Afghan Health Minister admits strained Pakistan ties, pivots to India for reliable medicine and vaccine supplies. A major shift in regional health diplomacy unfolds. Read the full analysis.
Trump's Deal with 9 Pharma Firms to Cut US Drug Prices
US President Donald Trump secures agreements with nine major pharmaceutical companies to reduce Medicaid and cash-pay drug prices, aiming to align US costs with other wealthy nations. Details inside.
India Plans Perpetual Licenses for Medical Devices
India plans to replace 5-year medical device licenses with perpetual approvals and standardize lab testing to cut compliance costs and attract investment. Read more.
Odisha Pharma Summit 2025 garners Rs 7,043 crore proposals
Odisha CM Mohan Majhi positions state as top pharma & medical devices investment destination. New policy & parks attract Rs 7,043 crore proposals, 45 MoUs signed. Read more.
India's AI Copyright Plan May Stifle Innovation
India's proposed blanket license for AI training data could raise costs, hurt creators, and drive startups abroad. Experts urge a balanced approach to foster innovation.
Shark Tank's Mittal on Ozempic Launch & 2026 Pharma Shift
Shark Tank India's Anupam Mittal comments on Ozempic's India launch, its ₹8,800/month price, and the 2026 patent expiry that could 5x the market. Read his take on fitness shortcuts vs. discipline.
Page 1 of 4